Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Transmitted HIV drug resistance in Asia

Transmitted HIV drug resistance in Asia REVIEW URRENT PINION a b c Annette H. Sohn , Padmini Srikantiah , Somnuek Sungkanuparph , and Fujie Zhang Purpose of review Surveillance for transmitted HIV drug resistance is essential to assessing the longer term sustainability and durability of first-line antiretroviral therapy (ART). Increases in pre-ART resistance would compromise the ability to achieve optimal and durable treatment outcomes using currently recommended antiretrovirals. Recent findings In the Asia region, many countries have conducted studies of transmitted resistance among recently HIV- infected and pre-ART patients. Data vary by methodology and resistance interpretation systems. Studies in some high-income settings have shown stabilizing or declining rates (e.g. Taiwan, Hong Kong), and increasing rates in others (e.g. Japan). In low-income and middle-income Asian countries, resistance has primarily been reported to be below WHO thresholds for moderate resistance (i.e. <5%). However, studies have identified an increased risk of resistance associated with male-to-male sex and/or higher rates among cohorts of MSM. Some countries still lack systematically collected transmitted resistance data. Summary To date, there does not appear to be a need for baseline resistance testing in most Asian settings for which there are data. However, MSM appear to be at higher risk of transmitted resistance and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Transmitted HIV drug resistance in Asia

Zhang, Fujie
Current Opinion in HIV and Aids , Volume 8 (1) – Jan 1, 2013
Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/transmitted-hiv-drug-resistance-in-asia-uyAxeE3bV2

References (44)

Copyright
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0b013e32835b804f
pmid
23196932
Publisher site
See Article on Publisher Site

Abstract

REVIEW URRENT PINION a b c Annette H. Sohn , Padmini Srikantiah , Somnuek Sungkanuparph , and Fujie Zhang Purpose of review Surveillance for transmitted HIV drug resistance is essential to assessing the longer term sustainability and durability of first-line antiretroviral therapy (ART). Increases in pre-ART resistance would compromise the ability to achieve optimal and durable treatment outcomes using currently recommended antiretrovirals. Recent findings In the Asia region, many countries have conducted studies of transmitted resistance among recently HIV- infected and pre-ART patients. Data vary by methodology and resistance interpretation systems. Studies in some high-income settings have shown stabilizing or declining rates (e.g. Taiwan, Hong Kong), and increasing rates in others (e.g. Japan). In low-income and middle-income Asian countries, resistance has primarily been reported to be below WHO thresholds for moderate resistance (i.e. <5%). However, studies have identified an increased risk of resistance associated with male-to-male sex and/or higher rates among cohorts of MSM. Some countries still lack systematically collected transmitted resistance data. Summary To date, there does not appear to be a need for baseline resistance testing in most Asian settings for which there are data. However, MSM appear to be at higher risk of transmitted resistance and

Journal

Current Opinion in HIV and Aids – Wolters Kluwer Health

Published: Jan 1, 2013

There are no references for this article.